22 ms·
This is very interesting but it lacks a key piece of information: how is this situation handled in other countries?
by riffraff 8y ago
This is very interesting but it lacks a key piece of information: how is this situation handled in other countries?
- monocasa 8y agoQuite a few countries aggressively nationalize orphan drug production facilities.
- ekianjo 8y agoIn Japan orphan drugs get priority reviews and patients don't pay anything (i.e. government/social security pays 100% for the rare disease). Companies who produce such drugs have almost carte blanche to make any price they want, since "nobody" is directly paying in the end.
- lovemenot 8y ago>> Companies who produce such drugs have almost carte blanche to make any price they want That's not really right since it's not open competition. MHLW sets a price for orphan drugs, which all companies must follow. In practice, the Ministry tends to use global prices as baseline in its negotiations with orphan drug suppliers, through their trade group representatives.